<DOC>
	<DOCNO>NCT02307500</DOCNO>
	<brief_summary>This single arm , single-stage , phase II trial evaluate activity Regorafenib patient metastatic solid tumor ( pancreatic cancer , ovarian cancer , melanoma , sarcoma progress standard therapy .</brief_summary>
	<brief_title>Regorafenib Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy</brief_title>
	<detailed_description>Each tumour assess . Regorafenib 40 mg tablet use study . Subjects receive 160 mg regorafenib po every day ( qd ) 3 week every 4 week cycle ( i.e. , 3 week , 1 week ) . Subjects continue treatment least one follow occurs ( main criterion ) : - Progressive Disease ( PD ) radiological assessment clinical progression - Death - Unacceptable toxicity - Subject withdraws consent - Treating physician determines discontinuation treatment subject 's best interest - Substantial non-compliance protocol</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>1 . Signed informed consent 2 . Patients older 18 year . 3 . Locally advanced , recurrent metastatic histologically confirm malignancy refractory available standard treatment , include Pancreatic cancer , Ovarian cancer , Melanoma , Sarcoma 4 . At least one measurable lesion accord Response Evaluation Criteria In solid tumor 5 . Eastern Cooperative Oncology Group Performance Status : 01 6 . Life expectancy least 12 week 7 . Adequate bone marrow , liver renal function assess follow laboratory : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count &gt; 1,500/mm3 Platelet count &gt; 100,000/μl White blood cell &gt; 3.0 x 109/L Total bilirubin &lt; 1.5 time upper limit normal Alanine amino transferase aspartate amino transferase &lt; 2.5 x upper limit normal ( &lt; 5 x upper limit normal patient liver involvement ) Serum creatinine &lt; 1.5 x upper limit normal Alkaline phosphatase &lt; 2.5 x Upper Limit Normal Prothrombin time / Partial prothrombin time &lt; 1.5 x Upper Limit Normal Lipase ≤ 1.5 x Upper Limit Normal 8 . Able swallow retain oral medication . 9 . Estimated creatinine clearance &gt; 30ml/min calculate use CockcroftGault equation 10 . Resolution toxic effect prior therapy NCI Common Terminology Criteria Adverse Event , Version 4.0 , grade ≤ 1 . 11 . Women childbearing potential men must agree use adequate contraception 1 . Prior treatment regorafenib . 2 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day start study drug 3 . Congestive heart failure &gt; New York Heart Association class 2 4 . Unstable angina ) , newonset angina.Myocardial infarction le 6 month start study drug 5 . Myocardial infarction le 6 month start study drug . 6 . Cardiac arrhythmia require antiarrhythmic therapy 7 . Uncontrolled hypertension . 8 . Pleural effusion ascites cause respiratory compromise 9 . Ongoing infection &gt; Grade 2 10 . Known history human immunodeficiency virus infection . 11 . Active hepatitis B C , chronic hepatitis B C require treatment antiviral therapy . 12 . Subjects seizure disorder require medication . 13 . History organ allograft . Subjects evidence history bleed diathesis , irrespective severity . 14 . Any hemorrhage bleeding event &gt; Common Toxicity Criteria Adverse Effects Grade 3 15 . Arterial venous thrombotic embolic event within 6 month start study medication 16 . Known history symptomatic metastatic brain meningeal tumor 17 . Suggestive consistent central nervous system disease 18 . Renal failure require hemoor peritoneal dialysis . 19 . Dehydration Common Toxicity Criteria Adverse Effects v. 4.0 Grade &gt; 1 . 20 . Substance abuse , medical , psychological social condition may interfere subject 's participation study evaluation study result . 21 . Known hypersensitivity study drug , study drug class , excipients formulation . 22 . Any illness medical condition unstable could jeopardize safety subject his/her compliance study . 23 . Interstitial lung disease ongoing sign symptom 24 . Persistent proteinuria CTCAE Grade 3 25 . Any malabsorption condition . 26 . Concomitant participation participation within last 30 day another clinical trial 27 . Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 4 week start receive study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>